Herpes simplex virus (HSV) is a common human pathogen. Despite current antivirals, it causes a significant medical burden. Drug resistant strains exist and they are especially prevalent in immunocompromised patients and in HSV eye infections. New treatment modalities are needed.
Methods
BALB/c mice were corneally infected with HSV and subsequently treated with a swarm of enzymatically created, Dicer-substrate small interfering RNA (siRNA) molecules that targeted the HSV gene UL29. Two infection models were used, one in which the infection was predominantly peripheral and another in which it spread to the central nervous system. Mouse survival, as well as viral spread, load, latency and peripheral shedding, was studied.
Results
The anti-HSV-UL29 siRNA swarm alleviated HSV infection symptoms, inhibited viral shedding and replication and had a favourable effect on mouse survival.
Conclusions
Treatment with anti-HSV-UL29 siRNA swarm reduced symptoms and viral spread in HSV infection of mice and also inhibited local viral replication in mouse corneas.
References
1.
PebodyR.G., AndrewsN., BrownD.The seroepidemiology of herpes simplex virus type 1 and 2 in Europe.Sex Transm Infect2004; 80: 185–191.
2.
BradleyH., MarkowitzL.E., GibsonT., McQuillanG.M.Seroprevalence of herpes simplex virus types 1 and 2–United States, 1999-2010.J Infect Dis2014; 209: 325–333.
3.
PuhakkaL., SarvikiviE., LappalainenM., SurcelH.M., SaxenH.Decrease in seroprevalence for herpesviruses among pregnant women in Finland: cross-sectional study of three time points 1992, 2002 and 2012.Infect Dis (Lond)2016; 48: 406–410.
4.
MäkiJ., PaavilainenH., GrénmanS., SyrjänenS., HukkanenV.Carriage of herpes simplex virus and human papillomavirus in oral mucosa is rare in young women: a long-term prospective follow-up.J Clin Virol2015; 70: 58–62.
LabetoulleM., KuceraP., UgoliniG.Neuronal propagation of HSV1 from the oral mucosa to the eye.Invest Ophthalmol Vis Sci2000; 41: 2600–2606.
7.
LabetoulleM., MailletS., EfstathiouS., DezeleeS., FrauE., LafayF.HSV1 latency sites after inoculation in the lip: assessment of their localization and connections to the eye.Invest Ophthalmol Vis Sci2003; 44: 217–225.
8.
FarooqA.V., ShuklaD.Herpes simplex epithelial and stromal keratitis: an epidemiologic update.Surv Ophthalmol2012; 57: 448–462.
9.
van VelzenM., van de VijverD.A., van LoenenF.B., OsterhausA.D., RemeijerL., VerjansG.M.Acyclovir prophylaxis predisposes to antiviral-resistant recurrent herpetic keratitis.J Infect Dis2013; 208: 1359–1365.
10.
RomanovskayaA., PaavilainenH., NygårdasM., BamfordD., HukkanenV., PoranenM.Enzymatically produced pools of canonical and Dicer-substrate siRNA molecules display comparable gene silencing and antiviral activities against herpes simplex virus.PLoS One2012; 7: e51019.
11.
PaavilainenH., LehtinenJ., RomanovskayaA.Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools.J Med Virol2016; 88: 2196–2205.
da SilvaA.S., RaposoJ.V., PereiraT.C., PintoM.A., de PaulaV.S.Effects of RNA interference therapy against herpes simplex virus type 1 encephalitis.Antivir Ther2016; 21: 225–235.
20.
SteinbachJ.M., WellerC.E., BoothC.J., SaltzmanW.M.Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection.J Control Release2012; 162: 102–110.
21.
LiZ., DuanF., LinL., HuangQ., WuK.A new approach of delivering siRNA to the cornea and its application for inhibiting herpes simplex keratitis.Curr Mol Med2014; 14: 1215–1225.
